BioAdvance Capital
Overview
BioAdvance is an early-stage venture capital firm dedicated to advancing human health. They invest in therapeutics, medical devices, digital health, diagnostics, and research tools, primarily focusing on seed and Series A opportunities in the Mid-Atlantic region from New York City to Washington, D.C. BioAdvance provides funding to enable companies to reach critical milestones.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Latus Bio | May 2026 | Series A | Co-investor |
| BobcatBio | Feb 2025 | Series A Extension | Lead |
| Bobcat Bio | Feb 2025 | Series A Extension | Co-investor |
| Tolerance Bio, Inc. | Dec 2024 | Seed | Co-investor |
| Palvella Therapeutics | Dec 2024 | Private Placement | Co-investor |
For institutional investors. Book with your work email.
Key People
Catherine Fink
Advisor - Venture Capital - MDTE Client
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is BioAdvance Capital based?
BioAdvance Capital is headquartered in Conshohocken, Pennsylvania, United States.
When was BioAdvance Capital founded?
BioAdvance Capital was founded in 2002.
How many portfolio companies does BioAdvance Capital have?
BioAdvance Capital has 32 portfolio companies in Caplight's dataset.
What are some companies in BioAdvance Capital's portfolio?
Recent investments visible on Caplight include Latus Bio, BobcatBio, Bobcat Bio, Tolerance Bio, Inc., Palvella Therapeutics.
What was BioAdvance Capital's most recent investment?
BioAdvance Capital's most recent investment on Caplight was in Latus Bio in 2026.
What sectors does BioAdvance Capital focus on?
BioAdvance Capital focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Consumer & Commerce, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Mobility, Transportation & Logistics, Enterprise Software, Enterprise Software, Enterprise Software, Enterprise Software, Enterprise Software, AI, Data & Cloud Infrastructure, Enterprise Software, Healthcare & Life Sciences, Enterprise Software, AI, Data & Cloud Infrastructure, Frontier & Industrial Tech.
What company stages does BioAdvance Capital focus on?
BioAdvance Capital typically invests at the Early stage.
What is BioAdvance Capital's AUM?
BioAdvance Capital's assets under management are estimated between $50.0M and $100.0M.